Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://giant-bike-company131566.joblog-life.com/313373/retatrutide-australia-a-promising-breakthrough-for-obesity-treatment